

April 8, 2019

Chief Material Licensing Branch  
US NRC Region III  
2443 Warrenville Road, Suite 210  
Lisle, IL 60532-4352

**REF: License No. 13-25945-01**  
**SUBJECT: License Amendment**


Dear Sir/Madam:

Please amend the license referred to above by changing the Ir-192 HDR source vendor "Mallinckrodt Medical B.V." listed in section 7.A., of the above named license, to "Curium Netherlands B.V.". The company name change will take place on May 15<sup>th</sup> of this year. Please find attached a notice letter from Curium.

I appreciate your attention to this matter. I will be glad to provide any additional information you may need in this regard. I can be contacted at (502) 554-2215 or via e-mail at [james.duce@mckesson.com](mailto:james.duce@mckesson.com)

Thanking you for your cooperation.

Sincerely,



James J. Duce, MS, DABR  
Radiation Safety Officer  
Encl.

RECEIVED APR 11 2019



November 13, 2018

**Subject: Notice letter - Change of name:  
Mallinckrodt Medical B.V. becomes Curium Netherlands B.V.**

Dear Valued Nuclear Medicine Partners and Customers,

As you were informed, the acquisition by IBA Molecular of Mallinckrodt Nuclear Imaging in January 2017 joined together two leading nuclear imaging businesses with complementary strengths, manufacturing capabilities, commercial footprints and operational networks. In April 2017 the combined Nuclear Medicine business adopted CURIUM as the trade name for the global organization.

Within this framework, we are delighted to announce that our local company name will change as of May 15<sup>th</sup>, 2019, from Mallinckrodt Medical B.V. to Curium Netherlands B.V. for the company to be clearly identified as a member of the global CURIUM organization.

Curium Netherlands B.V. remains the same legal entity with the same company banking account information, with no change except for the new entity name. Accordingly, this change of name does not affect the validity of agreements concluded with our company, which remain unchanged, in full force and effect, and with same terms and obligations.

We kindly ask you to update your records and internal systems accordingly and to address, as of May 15<sup>th</sup>, 2019, all future business and accounting correspondence with the new company name.

Should you have any specific questions or concerns, please channel them through [REDACTED]. We thank you for your cooperation and look forward to continuing our business relationship.

Yours faithfully

A handwritten signature in black ink, appearing to read "F. Lange", is written over the typed name.

Frank de Lange  
VP Manufacturing & Managing Director

Curium  
Mallinckrodt Medical B.V.  
Visit: Westerduinweg 3, 1755 LE Petten, The Netherlands  
Mail: P.O. Box 3, 1755 ZG Petten, The Netherlands

T +31 (0)224 56 78 90  
W [curiumpharma.com](http://curiumpharma.com)  
Trade register Alkmaar: 37042281